(November 22, 2017, 10:29 AM EST) -- LOS ANGELES — Lead plaintiffs in a securities class action lawsuit against a drug maker, certain of its current and former officers and directors and others have failed to plead loss causation in arguing that the defendants engaged in an illegal stock-pumping scheme in violation of federal securities laws, the defendants argue in a Nov. 10 motion to dismiss filed in California federal court (Arthur Kaye IRA FCC, et al. v. ImmunoCellular Therapeutics Ltd., et al., No. 17-3250, C.D. Calif.)....